D
0.420
0.01 (1.20%)
| Previous Close | 0.415 |
| Open | 0.405 |
| Volume | 1,222,396 |
| Avg. Volume (3M) | 2,396,673 |
| Market Cap | 234,892,976 |
| Price / Book | 37.46 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 |
| Operating Margin (TTM) | -4,556.12% |
| Diluted EPS (TTM) | -0.040 |
| Quarterly Revenue Growth (YOY) | 116.00% |
| Total Debt/Equity (MRQ) | 2.18% |
| Current Ratio (MRQ) | 4.77 |
| Operating Cash Flow (TTM) | -18.78 M |
| Levered Free Cash Flow (TTM) | -10.23 M |
| Return on Assets (TTM) | -79.26% |
| Return on Equity (TTM) | -524.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | DIMERIX FPO [DXB] | - | - |
AIStockmoo Score
1.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 23.39% |
| % Held by Institutions | 0.61% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |